Sildenafil for Health & Longevity

Evidence Review created on 09/26/2026 using AI4L + evidence-mcp / Grok 4

Also known as: Viagra, Revatio, Liqrev, Sildenafil Citrate, UK-92480

Motivation

Sildenafil is a prescription oral medication. It was explored first for heart-related chest pain, then used widely for difficulty getting or keeping an erection, and later for high blood pressure in the arteries of the lungs. It slows breakdown of a messenger that lets blood vessels relax when a widen-vessel signal is already present. Adults focused on long-term health have asked whether that action could matter for the heart and the brain as well.

The medication has been in routine use for more than two decades. Controlled trials support the erection effect in men and a walking-distance effect when lung-artery pressure is high. Separate from those uses, large medical-record studies find fewer later heart events, deaths, and dementia diagnoses among men who were prescribed it. Those patterns do not show causation. Men who receive a prescription also differ in health and sexual activity.

This review examines what sildenafil is, how it acts, which benefits and harms human studies support, and how dosing, interactions, and monitoring are described. It is framed for adults pursuing a longer healthy life, and it keeps trial-proven effects separate from associations that remain unproven.

Benefits - Risks - Protocol - Conclusion

High-level commentary on sildenafil, erection difficulty as a vessel signal, and the claim that this medication might extend life.

Chris Kresser: site searches for sildenafil and for this drug class returned no on-topic pieces. FoundMyFitness has a short research digest on Viagra in mice carrying a recessive retinitis-pigmentosa gene, which is not a high-level overview, so it is not listed. Five sources met the bar; the list is not padded past that.

Grokipedia

  • Sildenafil

    Reference page on what sildenafil is, its approved uses, and how it relaxes blood vessels when a widen-vessel signal is present.

Examine

No dedicated Examine.com article on sildenafil was found. Examine.com does not typically cover prescription medications.

ConsumerLab

No dedicated ConsumerLab article on sildenafil was found. ConsumerLab does not typically cover prescription medications. Public hits were recalls of supplements that secretly contained the drug, not a review of the drug itself.

Systematic Reviews

Five reviews cover erection efficacy, heart outcomes and death, Alzheimer disease, melanoma, and a rare optic-nerve injury.

Mechanism of Action

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic guanosine monophosphate (cGMP), a messenger that relaxes smooth muscle. Sexual stimulation and some other signals release nitric oxide (NO), a short-lived gas that tells vessels to widen. NO turns on guanylate cyclase (the enzyme that makes cGMP), and PDE5 then clears that messenger. Blocking PDE5 lets cGMP last longer only where NO has already been released. Sildenafil has no direct relaxant effect on isolated penile muscle, so an erection still requires stimulation.

The same path operates in lung arteries and, more modestly, in arteries elsewhere in the body. That is the basis of the lung-pressure effect and of a small drop in systemic blood pressure. Sildenafil prefers PDE5 but also inhibits PDE6 (a retinal enzyme involved in sensing light) enough that some people notice a transient blue-green color tinge.

After an oral dose, mean absolute bioavailability (the share of a dose that reaches the blood) is about 41%. The steady-state volume of distribution is about 105 L, so the drug spreads into tissues. A high-fat meal delays the peak by about an hour and lowers peak concentration. The elimination half-life is 3 to 5 hours. Clearance is mainly through CYP3A4 (a liver enzyme that clears many drugs). Strong blockers of that enzyme raise exposure several-fold. The main circulating metabolite (the compound the body makes from the drug) is UK-103,320. These healthy-volunteer studies were done by the manufacturer, Pfizer. (Nichols et al., 2002; Langtry & Markham, 1999)

Historical Context & Evolution

Sildenafil, development code UK-92480, was pursued by Pfizer as an oral medication for angina (chest pain from narrowed heart arteries). In early studies the angina effect disappointed, while erections were an unexpected observation. Development then shifted to erectile dysfunction. Approval for that use, as Viagra, followed randomized trials in the late 1990s. A later approval, as Revatio, covered pulmonary arterial hypertension (PAH, high blood pressure in the lung arteries) after a trial showed longer walking distance and lower lung-artery pressure.

The early public fear was that a vessel-widening drug plus the effort of sex would cause heart attacks. Controlled trials did not show more cardiovascular events than placebo. After approval, reports of heart attack and sudden death appeared, mostly in men who already had cardiovascular disease and often around sexual activity. Those reports do not separate the drug, the exertion, and the underlying disease.

Later medical-record research associated prescriptions with fewer deaths, heart events, and dementia diagnoses. The studies are large and point the same way, and they remain open to confounding by who seeks care. A randomized trial in one common form of heart failure found no gain in exercise capacity. Melanoma looked more common in some user studies; other analyses found no dose pattern and a similar link with a sun-related skin cancer, which argues against a specific drug effect. Finger-artery spasm in the cold and effort at high altitude have also been studied, as narrower uses. None of the later chapters is a closed case.

Expected Benefits

High 🟩 🟩 🟩

Erectile function

Sildenafil improves erections during sexual stimulation in men with erectile dysfunction. In Pfizer-sponsored trials, 69% of intercourse attempts succeeded on sildenafil versus 22% on placebo, and a 2025 meta-analysis of this drug class supports benefit in diabetes. Stimulation is required. This is an erection result, not evidence of a longer life. (Goldstein et al., 1998; Zhu et al., 2025)

Magnitude: In the flexible-dose trial, 69% of intercourse attempts succeeded on sildenafil versus 22% on placebo; at 100 mg the erection-achievement score rose from 2.0 to 4.0 out of 5.

Walking capacity in pulmonary arterial hypertension

In PAH, sildenafil lengthens walking distance and lowers lung-artery pressure. A Pfizer-sponsored randomized trial of 278 adults found this over 12 weeks, and a later randomized trial that added sildenafil to epoprostenol also lengthened the walk. It is a disease treatment in people who already have PAH, not a fitness result in healthy adults. (Galiè et al., 2005; Simonneau et al., 2008)

Magnitude: Placebo-corrected six-minute walk gains of 45 m, 46 m, and 50 m at 20 mg, 40 mg, and 80 mg three times daily over 12 weeks.

Medium 🟩 🟩

Cardiovascular events and death

Cohort studies associate PDE5-inhibitor use, and sildenafil specifically, with fewer cardiovascular events and deaths, including after a heart attack when compared with alprostadil. Treated men differ in health and sexual activity, so the pattern is an association. A randomized trial in heart failure with preserved ejection fraction (pumping fraction stays normal) did not improve exercise capacity. Causation is not established. (Soulaidopoulos et al., 2024; Jehle et al., 2025; Andersson et al., 2017; Redfield et al., 2013)

Magnitude: Class-level risk ratio (RR, how many times as often an outcome occurs) 0.78 (95% confidence interval (CI, the range compatible with the data) 0.69–0.89) for major adverse cardiovascular events (MACE, a pooled count of events such as heart attack and stroke) and 0.70 (0.56–0.87) for death; sildenafil-specific RR 0.76 for death in one large matched cohort.

Alzheimer disease and dementia

Observational studies link sildenafil with fewer later Alzheimer diagnoses. A five-study meta-analysis and later comparisons agree on direction but not on size. No randomized dementia trial exists. Who stays sexually active, and who receives a prescription, can confound the link, so this is not proof of prevention. (Chua et al., 2025; Fang et al., 2021; Jehle et al., 2025)

Magnitude: Pooled observational hazard ratio (HR, a comparison of rates over time) 0.47 (95% CI 0.27–0.82) for Alzheimer disease versus non-use; individual studies span about a 25% to a 69% lower associated risk.

Low 🟩

Endothelial function ⚠️ Conflicted

Endothelial function (vessel-lining responsiveness) looked better on an arm-artery test after prolonged use in thirteen trials, but small-vessel tests were negative and results disagreed sharply. The authors call the evidence unconvincing. The net reading is an unconfirmed artery-widening signal, not an established clinical effect. (D’Andrea et al., 2019)

Magnitude: Brachial flow-mediated dilation (FMD, how much an arm artery widens after a brief squeeze) improved (P<0.0001; P is how unlikely a gap this large is if there were no real difference), but inconsistency (I², a measure of that scatter) was 92%, and no stable effect size is reported.

Speculative 🟨

Direct effects on aging biology

No trial has tested sildenafil for lifespan. Cells grown from people with Alzheimer disease showed less of a disease-related protein change after sildenafil, a laboratory finding only. (Gohel et al., 2024)

Benefit-Modifying Factors

  • Liver-enzyme activity: Clearance is mainly by CYP3A4. Lower activity, from genes or from blocking drugs, raises blood levels and can strengthen both the erection effect and headache or flushing. Routine gene testing is not an established dosing tool.

  • Baseline blood pressure: A lower starting pressure leaves less room for the short pressure drop. In pulmonary arterial hypertension, the starting lung-artery pressure and walk distance frame how large those changes look. No blood test predicts the erection response.

  • Baseline erection difficulty: Milder difficulty tends to respond more fully. Diabetes and nerve injury after prostate surgery still respond in trials, but less often than primarily psychological cases. Stimulation is still required.

  • Sex: Erection trials enrolled men. Lung-artery trials included women and men. Death and dementia associations come almost entirely from men treated for erection difficulty. No sexual-function use is established in women.

  • Other illnesses: The walking benefit is in PAH. Heart failure with preserved ejection fraction did not gain fitness in a randomized trial. Heart and dementia signals are in men who already had erection difficulty, often with vessel-disease risk.

  • Age: Erection efficacy was seen both below and above 65 years. Clearance is slower after 65, so the same dose produces higher exposure and labeled regimens start lower.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Headache

Headache is the most common adverse event and fits with vessel widening. It was dose-related in fixed-dose erection trials and remained common with the flexible doses used in practice. Episodes in the trials were mostly transient. Stopping for adverse events overall was similar to placebo, 2.5% versus 2.3%, in the prescribing-information summary. (Viagra prescribing information; Goldstein et al., 1998)

Magnitude: 16% at 25 mg, 21% at 50 mg, and 28% at 100 mg, versus 7% on placebo, in fixed-dose trials; 16% versus 4% with flexible dosing.

Flushing

Flushing (a warm redness of the skin) is a direct result of widened skin vessels. It tracked with dose in the erection development program and was among the events occurring in 6% to 18% of men in the flexible-dose pivotal trial. It is usually short-lived and is not itself an organ injury. (Viagra prescribing information; Goldstein et al., 1998)

Magnitude: 10% at 25 mg, 19% at 50 mg, and 18% at 100 mg, versus 2% on placebo; 10% versus 1% with flexible dosing.

Dyspepsia (heartburn and indigestion)

Heartburn and indigestion reflect relaxation of the muscle at the lower end of the esophagus, the same smooth-muscle action that widens vessels. The symptom was clearly dose-related, rising sharply at 100 mg. It is uncomfortable rather than dangerous for most people, and it was part of the common complaints in the pivotal trial. (Viagra prescribing information; Goldstein et al., 1998)

Magnitude: 3% at 25 mg, 9% at 50 mg, and 17% at 100 mg, versus 2% on placebo; 7% versus 2% with flexible dosing.

Nasal congestion

Nasal congestion comes from widened vessels in the nasal lining. It was more frequent than placebo at every tested dose and was most noticeable at 100 mg. The complaint is a nuisance adverse event, not an infection, and it can matter if a dose overlaps sleep. (Viagra prescribing information; Langtry & Markham, 1999)

Magnitude: 4% at 25 mg, 4% at 50 mg, and 9% at 100 mg, versus 2% on placebo; 4% versus 2% with flexible dosing.

Color-tinge vision

Some people see a blue-green tinge, more light sensitivity, or brief blur, from partial inhibition of retinal PDE6 rather than the optic-nerve injury discussed separately. In fixed-dose trials it was uncommon at 25–50 mg and 11% at 100 mg, and it is described as transient. One person in the flexible-dose studies stopped because of it. (Viagra prescribing information; Langtry & Markham, 1999)

Magnitude: Abnormal vision in 1%, 2%, and 11% at 25 mg, 50 mg, and 100 mg, versus 1% on placebo; 3% versus 0% with flexible dosing.

Drop in blood pressure

Sildenafil lowers systemic blood pressure briefly by widening arteries. Healthy volunteers had a mean maximum fall in sitting pressure of 8.3/5.3 mmHg, and 100 mg added about 8/7 mmHg on amlodipine, with dizziness at 2% versus 1% on placebo. The same fall becomes dangerous with nitrates. These figures are from the manufacturer’s prescribing information. (Viagra prescribing information; Langtry & Markham, 1999)

Magnitude: Mean maximum fall in sitting pressure of 8.3/5.3 mmHg in healthy volunteers; an added 8/7 mmHg when 100 mg was combined with amlodipine 5 or 10 mg.

Medium 🟥 🟥

No risk is graded Medium: a Medium grade would require one randomized trial, or consistent observational studies, of a clinical harm not already shown across repeated trials, and the remaining harms are a single cohort, case reports, or conflicting observational signals.

Low 🟥

Sudden hearing loss

One large cohort of the drug class, not sildenafil alone, found a small rise in sudden nerve-related hearing loss with current use. Added cases were few per 10,000 people per year. Spontaneous reports have not proved cause. (Liu et al., 2018)

Magnitude: Adjusted HR 1.25 (95% CI 1.01–1.55) for current use versus nonuse, a risk difference of 1.97 cases per 10,000 person-years.

Non-arteritic anterior ischemic optic neuropathy ⚠️ Conflicted

This optic-nerve injury (NAION, sudden vision loss from poor flow) has no clear class-wide link in a meta-analysis, while the sildenafil subgroup is higher. The net reading is a possible increase that is not established as causal. (Liu et al., 2018)

Magnitude: Sildenafil subgroup RR 2.25 (95% CI 1.29–3.94) in one meta-analysis; the class-wide one-month RR was 1.16 (0.98–1.39) and not statistically significant.

Melanoma ⚠️ Conflicted

Meta-analyses find a small class-level melanoma association. The sildenafil-only estimate was not significant, and there was no dose pattern. The net reading is that a causal effect of sildenafil is not established. (Kreuz et al., 2025; Loeb et al., 2017)

Magnitude: Class HR 1.10 (95% CI 1.03–1.17) for melanoma; sildenafil-specific odds ratio (OR, how the odds of the outcome compare) 1.85 (0.97–3.51), not statistically significant.

Priapism (prolonged painful erection)

Prolonged painful erection appears in case reports and is called infrequent after marketing, not a counted trial event. Episodes beyond 4 hours need urgent care because longer ones can scar tissue. Sickle cell disease and penile scarring are expected to raise that risk. (Sur & Kane, 2000)

Magnitude: Not quantified in available studies. Controlled trials have not reported a rate, and the prescribing information describes post-marketing events only as infrequent.

Speculative 🟨

Risk-Modifying Factors

  • CYP3A4 blockers and low enzyme activity: Higher exposure raises the chance of hypotension (a blood-pressure drop), headache, and color-tinge vision. Ritonavir increased exposure about 11-fold in interaction studies.

  • Baseline blood pressure: A resting pressure under 90/50 mmHg leaves little margin. Pressures above 170/110 mmHg were not studied in the erection program.

  • Sex: Adverse-event tables for erection use are from men. Priapism is male-specific. Vasodilator effects in lung-artery trials occurred in women and men.

  • Predisposing conditions: Recent heart attack, stroke, or dangerous rhythm, unstable angina (chest pain at rest or worsening), prior NAION, retinitis pigmentosa (an inherited retinal disease), sickle cell disease, and penile scarring each concentrate a different harm.

  • Age: After 65, higher blood levels at the same dose mean more hypotension and headache. NAION background risk also rises from about age 50.

Key Interactions & Contraindications

  • Organic nitrates and nitrites (nitrate heart medicines: nitroglycerin, isosorbide dinitrate, isosorbide mononitrate, amyl nitrite): Absolute contraindication. Combined use can cause severe hypotension. No safe gap is established; levels are much lower at 24 hours, but nitrate safety then is unknown.

  • Guanylate cyclase stimulators (riociguat): Absolute contraindication. Additive hypotension. The label forbids combined use. This interaction is labeled, not theoretical.

  • Alpha-blockers (vessel-relaxing drugs such as doxazosin and tamsulosin): Caution. Both widen vessels and together can cause symptomatic hypotension. Labeled sequence: stable alpha-blocker first, then sildenafil at 25 mg.

  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) and erythromycin or saquinavir: Caution, dose cap. Ritonavir: 25 mg and no more than 25 mg in 48 hours (about an 11-fold exposure rise). For the others, the labeled start is 25 mg. Prevents hypotension and prolonged erection.

  • CYP3A4 inducers (bosentan, rifampin): Caution, weaker effect. Bosentan lowered exposure about 63%. Rifampin is expected to lower it more. The loss of effect matters most for the three-times-daily lung-artery regimen.

  • Cimetidine (Tagamet): Caution, lower start. This over-the-counter acid reducer, at 800 mg, raised sildenafil levels by 56%. A 25 mg start limits headache and a larger blood-pressure drop.

  • Other blood-pressure drugs (amlodipine): Caution, monitor. Sildenafil 100 mg added about 8/7 mmHg to amlodipine. Standing pressure is checked after the first combined doses.

  • Other PDE5 inhibitors (tadalafil, vardenafil, avanafil) and other erection treatments: Caution. Combinations were not studied and may drop blood pressure further. Stacked doses sit outside labeled use.

  • Nitric-oxide-supporting supplements (L-Arginine, L-Citrulline, beet nitrate): Caution. They push the same messenger sildenafil preserves, so the blood-pressure drop can add up. Standing pressure is the check; timing separation does not remove the overlap.

  • Grapefruit juice: Caution. It can block CYP3A4 and raise exposure, with more hypotension and headache. Large daily amounts are the concern; a 25 mg start is the mitigating step.

Populations who should avoid Sildenafil:

  • Anyone using organic nitrates or nitrites in any form, regularly or intermittently
  • Anyone using riociguat
  • Known hypersensitivity to sildenafil
  • Resting blood pressure below 90/50 mmHg
  • Resting blood pressure above 170/110 mmHg
  • Myocardial infarction (a heart attack), stroke, or life-threatening arrhythmia (a dangerous heart rhythm) within the last 6 months
  • Unstable angina from heart failure or coronary disease
  • Prior NAION, when use would be elective, because recurrence risk is higher
  • Hereditary retinitis pigmentosa (a retinal disease in which PDE6 can be genetically abnormal); the erection trials excluded this group

Risk Mitigation Strategies

  • Nitrate screen: A pre-dose check for any nitrate or nitrite is what prevents a severe blood-pressure collapse.

  • Low starting dose: The labeled start is 25 mg after age 65, if creatinine clearance is under 30 mL/min, with liver impairment, an alpha-blocker, or a strong CYP3A4 blocker, to limit hypotension and headache.

  • Once-daily cap: A second dose the same day is outside the label. That cap limits stacked hypotension and prolonged erection.

  • Stop for vision or hearing: Protocols call for stopping and urgent care after sudden vision loss, or a sudden hearing drop. That is the setting of NAION and hearing-loss reports.

  • Four-hour erection rule: An erection still present at 4 hours needs urgent care, to limit progression to tissue-damaging priapism.

  • Pressure check: Seated and standing blood pressure before the first dose and after the first one or two doses, especially with other pressure drugs, catches symptomatic hypotension.

Therapeutic Protocol

  • As-needed erection regimen: Pfizer’s labeled regimen, used in the pivotal trials, is 50 mg orally about 1 hour before sexual activity, adjustable to 25–100 mg, no more than once a day.

  • Lung-artery regimen: Pfizer’s PAH dosing in the pivotal trial is 20 mg orally three times daily. That schedule is a disease treatment, not a longevity schedule, and it was tied to the walking-distance result.

  • Off-label single daily dose: A once-daily 20–25 mg pattern is sometimes described for vessel exposure. No named clinic standard is established. It differs from the erection-trial regimen and the 12-week lung-artery regimen.

  • Time of day: No clock hour is preferred. Erection doses are timed about 1 hour before activity, with onset in 30–60 minutes and a useful window of about 4 hours. Lung-artery doses are spaced across waking hours.

  • Half-life and splitting: Half-life is 3–5 hours. Erection use is one dose. Splitting across the day is the PAH schedule (three doses), not the erection schedule.

  • Genes: CYP3A4 variants may change exposure, but routine gene testing does not set the dose. Known enzyme-blocking drugs are the practical trigger for 25 mg.

  • Sex: The erection regimen was studied in men. The three-times-daily lung regimen was studied in women and men.

  • Age: Over 65, the labeled start is 25 mg because exposure is higher. Efficacy itself was seen on both sides of that age.

  • Baseline labs: Creatinine clearance under 30 mL/min, or hepatic impairment, is a reason to start at 25 mg. Resting pressure sets the hypotension margin.

  • Other conditions: Alpha-blockers, strong CYP3A4 blockers, and recent heart attack, stroke, or unstable angina change the dose or rule the drug out. Sexual stimulation is still required for an erection effect.

Discontinuation & Cycling

  • How long: Erection use is as-needed and can be occasional or ongoing. PAH use is continuous. Stopping one schedule does not require stopping a different indication on a fixed timetable.

  • Withdrawal: No withdrawal syndrome is described. Erections return to the person’s baseline when the drug is absent. There is no taper for receptor rebound.

  • Taper: As-needed doses can simply stop. No taper protocol is established, because exposure is already gone within about a day given the 3–5 hour half-life.

  • Cycling: Cycling is not required to keep efficacy. Effect was maintained in studies out to about a year. A drug holiday is a preference, not a demonstrated necessity.

Sourcing and Quality

  • Prescription product: Sildenafil is a prescription oral medication, supplied as film-coated tablets of 25, 50, and 100 mg for erection use and 20 mg for PAH. It is not a dietary supplement.

  • What to look for: Tablets that match an approved product, with the dose printed on the tablet, dispensed by a licensed pharmacy. Dose strength matches the intended regimen.

  • Generics: Multiple generic sildenafil products are approved and widely dispensed. The original brands were Viagra and Revatio. Brand and generic are not for use on the same day.

  • Adulterated supplements: ConsumerLab’s public recall listings, as of 2026, describe sexual-enhancement supplements recalled because they contained undeclared sildenafil. Those products bypass dose control and nitrate screening. (ConsumerLab sildenafil search)

Practical Considerations

  • Time to effect: Erection facilitation is often noticeable in 30–60 minutes and is relevant for about 4 hours. Heart, death, and dementia associations, where reported, reflect years of prescribing, not days of use.

  • Common pitfalls: Combining with a nitrate; expecting an erection without sexual stimulation; taking a second dose the same day; using the drug to exercise through unstable heart disease; reading a cohort association as proven life extension.

  • Regulatory status: Approved for erectile dysfunction and, in the 20 mg product, for PAH. Use for longevity, dementia prevention, or a once-daily vascular experiment is off-label.

  • Cost and access: After generic entry the medication is generally inexpensive relative to the original brand and is available through ordinary prescription channels, so access is a prescribing issue more than a cost barrier.

Interaction with Foundational Habits

  • Sleep: Indirect. Nasal congestion, headache, or flushing can fragment sleep if the dose overlaps the night. The 3–5 hour half-life makes a late dose more likely to do that. No trial shows better sleep.

  • Nutrition: Direct pharmacokinetic, not a nutrient drain. A high-fat meal delays the peak by about an hour and cuts peak concentration about 29%, with little change in total exposure. Grapefruit can raise levels via CYP3A4, especially large intake on dosing days.

  • Exercise: Direction depends on setting. Potentiating for walking distance in PAH via lung-vessel widening; none for peak oxygen use in a 24-week heart-failure trial; no evidence of gain or blunting in ordinary training. Chest pain during effort is a stop signal.

  • Stress management: Indirect. Reliable erections can ease performance anxiety around sex. That is a psychological consequence of the erection effect, not a measured change in cortisol or a stress-hormone action. No timing trick relative to stress practice is established.

Monitoring Protocol & Defining Success

Before a first dose, the useful checks are a medication review and a blood-pressure reading. The review looks for nitrates, riociguat, alpha-blockers, and strong CYP3A4 inhibitors, plus prior optic-nerve injury, retinitis pigmentosa, penile scarring, sickle cell disease, a heart attack, stroke, or dangerous rhythm within 6 months, unstable chest pain, or resting pressure below 90/50 mmHg or above 170/110 mmHg. Estimated glomerular filtration rate (eGFR, a blood estimate of kidney filtering) and alanine aminotransferase (ALT, a liver enzyme) decide whether to start at 25 mg, because severe kidney or liver impairment raises exposure. Ongoing checks are seated and standing pressure after the first doses, at about 4 weeks, then every 6–12 months, and when another pressure-lowering or enzyme-blocking drug is added.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure 100–120 / 60–80 mmHg Catches a low-pressure adverse effect before a nitrate or a new drug makes it dangerous Label cautions against use below 90/50 mmHg or above 170/110 mmHg. Many clinic targets use under 130/80 mmHg. Measure seated and after standing 1 minute.
eGFR Above 90 mL/min/1.73 m² Severe impairment raises drug exposure and changes the starting dose No dose change for mild or moderate impairment. Creatinine clearance under 30 mL/min: the labeled start is 25 mg. Fasting is not required.
ALT No drug-specific target; follow the person’s own baseline Liver impairment raises exposure The labeled start is 25 mg if hepatic impairment such as cirrhosis is present. A rise from that person’s baseline matters more than a single population cutoff.

Qualitative markers:

  • Erection quality during sexual stimulation, compared with the person’s own baseline
  • Headache, flushing, heartburn, and nasal congestion after a dose
  • Blue-green color tinge or new blur, distinct from sudden vision loss
  • Sudden change in hearing, including ringing or dizziness with the hearing change
  • Lightheadedness on standing, especially in the first hours after a dose
  • Chest pain or marked shortness of breath with sexual activity or exercise

Emerging Research

  • Brain small-vessel injury: Sildenafil for Microvasculopathy in Chronic TBI (NCT05782244) is a phase 2 trial, recruiting, planned for about 160 people with traumatic brain injury. A positive or null vessel result would strengthen or weaken the idea that sildenafil matters for brain blood flow.

  • Leg-artery walking pain: VIRTUOSE (NCT03686306) is a phase 3 trial, active, about 106 people with peripheral artery disease, testing walking distance. A null result would argue against a general circulation benefit outside the lung arteries.

  • No Alzheimer outcomes trial located: A ClinicalTrials.gov search on 2026-09-26 for sildenafil in Alzheimer disease, dementia, cognitive disorders, aging, or longevity found no recruiting trial with Alzheimer disease as the condition. The dementia association therefore remains observational. (Chua et al., 2025)

  • Heart outcomes still observational: The lower rate of heart events and death is a cohort finding. A randomized comparison of those events would be capable of confirming or erasing it, which is the uncertainty Soulaidopoulos et al., 2024 state in their own conclusion.

Conclusion

Sildenafil is an oral medication that helps blood vessels relax when a widen-vessel signal is already present. Two uses are well studied in controlled trials sponsored by Pfizer, the company that developed the drug: erections in men who have difficulty, and walking ability when pressure is high in the lung arteries. Record studies find fewer heart attacks, deaths, and dementia diagnoses among men prescribed this medication or similar ones. That pattern is repeated and still only an association, because those men differ in health and behavior. A controlled study in one common form of heart failure did not improve exercise capacity.

Trial harms that recur are headache, flushing, heartburn, nasal congestion, a brief color change in vision, and a small drop in blood pressure. An erection that will not settle, sudden vision loss, and sudden hearing loss are uncommon and less firmly tied to the drug, but serious when they occur. A small melanoma link fails basic checks for a true drug effect. Nitrate heart medicines, and the lung medicine riociguat, can combine with sildenafil to drop blood pressure dangerously. That interaction is the hard boundary.

Erection dosing in the trials is one oral dose before sexual activity, set lower in older age, with low kidney filtering, liver disease, and certain other drugs. Several doses a day belong to lung-artery disease. Once-daily low doses sit outside those trials. Survival and dementia remain unsettled, separate from the erection and walking effects the trials measured.

Top - Benefits - Risks - Protocol